VivoSeq
Other

Overall Survival

18

Pipeline Programs↗

1

Active Trials↗

16

Companies Involved↗

Overall Survival is an emerging landscape with 18 programs across 16 companies. The most active players are Amgen, Johnson & Johnson, Roche. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

75/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Roche logo

Roche

1 program

Phase 2I

Imclone

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

14 of 18 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody422%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Terminated2 · 22%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Not yet recruiting·—·Phase 3·NCT07338981·142 enrolled
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Completed·Astellas logoAstellas·N/A·NCT03328364·211 enrolled
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Completed·Pfizer logoPfizer·N/A·NCT06086340·779 enrolled
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
Completed·Sanofi logoSanofi·Phase 2/3·NCT00290953·432 enrolled
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
Completed·MMedSIR·N/A·NCT06525675·419 enrolled
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Completed·Bayer logoBayer·N/A·NCT02450812·86 enrolled
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
Completed·Pfizer logoPfizer·N/A·NCT04735367·42 enrolled
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Terminated·—·Phase 2·NCT01044225·12 enrolled
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
Terminated·Amgen logoAmgen·Phase 2·NCT00613730·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)